Sign in
4

Changes in Ownership

AGIOS PHARMACEUTICALS, INC. Filed Acc 0001439222-26-000040

Chief Medical Officer sold 4,055 shares at $28.96 ($117,433)

  • Chief Medical Officer acquired 13,666 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Gheuens Sarah · Chief Medical Officer

Table I: Non-derivative

6 lines
Date Transaction Shares Price Value Owned after D/I
2026-03-02 Exercise or conversion : show line 1 in the form 10b5-1 +4,000 68,795 D
2026-03-02 Sale : show line 2 in the form 10b5-1 −1,187 $28.96 $34,376 67,608 D
2026-03-02 Exercise or conversion : show line 3 in the form 10b5-1 +5,666 73,274 D
2026-03-02 Sale : show line 4 in the form 10b5-1 −1,681 $28.96 $48,682 71,593 D
2026-03-02 Exercise or conversion : show line 5 in the form 10b5-1 +4,000 75,593 D
2026-03-02 Sale : show line 6 in the form 10b5-1 −1,187 $28.96 $34,376 74,406 D
Open-market sales · 4,055 sh · avg $28.96 · $117,433

Table II: Derivative

6 lines
Date Transaction Shares Owned after D/I
2026-03-01 Grant or award : show line 7 in the form 10b5-1 Restricted stock units +14,000 14,000 D
2026-03-01 Grant or award : show line 8 in the form 10b5-1 Restricted stock units +22,000 22,000 D
2026-03-01 Grant or award : show line 9 in the form 10b5-1 Stock options (right to buy) +52,000 52,000 D
2026-03-02 Exercise or conversion : show line 10 in the form 10b5-1 Restricted stock units −4,000 0 D
2026-03-02 Exercise or conversion : show line 11 in the form 10b5-1 Restricted stock units −5,666 5,667 D
2026-03-02 Exercise or conversion : show line 12 in the form 10b5-1 Restricted stock units −4,000 8,000 D
Loading xslF345X05/wk-form4_1772572555.xml…